Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT) will report third quarter 2025 financial results after market close on Wednesday, November 5, 2025. Management will host a webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will be available on the company Investors web page at www.adaptivebiotech.com, and the webcast will be archived and available for replay within 24 hours.
Positive
- None.
Negative
- None.
News Market Reaction 34 Alerts
On the day this news was published, ADPT gained 9.95%, reflecting a notable positive market reaction. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. The stock closed at $17.14 on that trading session. This price movement added approximately $236M to the company's valuation, bringing the market cap to $2.61B at that time.
Data tracked by StockTitan Argus on the day of publication.
SEATTLE, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
FAQ
When will Adaptive Biotechnologies (ADPT) report Q3 2025 results?
What time is the Adaptive Biotechnologies (ADPT) Q3 2025 earnings call?
Where can investors listen to the Adaptive Biotechnologies (ADPT) Q3 2025 webcast?
Will the Adaptive Biotechnologies (ADPT) Q3 2025 webcast be available after the call?
Is Adaptive Biotechnologies (ADPT) a commercial stage biotechnology company?
